These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 35859710)

  • 41. Guselkumab for treatment of moderate-to-severe plaque psoriasis: real-life effectiveness and drug-survival for up to 148 weeks.
    Galluzzo M; Marcelli L; Vellucci L; Paganini C; Maffei V; Tofani L; Belcastro A; Bianchi L; Talamonti M
    Expert Opin Biol Ther; 2023 Apr; 23(4):371-381. PubMed ID: 36971507
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of previous biologic use and body weight on the effectiveness of guselkumab in moderate-to-severe plaque psoriasis: a real-world practice.
    Hung YT; Lin YJ; Chiu HY; Huang YH
    Ther Adv Chronic Dis; 2021; 12():20406223211046685. PubMed ID: 34729147
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years.
    Griffiths CEM; Papp KA; Kimball AB; Randazzo B; Song M; Li S; Shen YK; Blauvelt A
    J Drugs Dermatol; 2018 Aug; 17(8):826-832. PubMed ID: 30124721
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effectiveness of IL-23 Inhibitor Guselkumab in Real-World Chinese Patients with Psoriasis During a 20-Week Period.
    Chan Y; Tong BSB; Ngan PY; Au CS
    Psoriasis (Auckl); 2021; 11():53-58. PubMed ID: 34104632
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effectiveness of Biologics, Patient-Reported Outcomes, and Clinical Photography in a Subset of Patients with Moderate-to-Severe Psoriasis: Week 12 Results from the Psoriasis Study of Health Outcomes (PSoHO).
    Travaglini M; Maul JT; Kors C; Zaheri S; Gerwien J; Müller M; Brnabic A; Sabatino S; Schuster C; Tsai TF
    Clin Cosmet Investig Dermatol; 2023; 16():2971-2983. PubMed ID: 37881205
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study.
    Ohtsuki M; Kubo H; Morishima H; Goto R; Zheng R; Nakagawa H
    J Dermatol; 2018 Sep; 45(9):1053-1062. PubMed ID: 29905383
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Real-world effectiveness of guselkumab in patients with psoriasis: Health-related quality of life and efficacy data from the noninterventional, prospective, German multicenter PERSIST trial.
    Gerdes S; Bräu B; Hoffmann M; Korge B; Mortazawi D; Wiemers F; Wegner S; Personke Y; Gomez M; Sticherling M
    J Dermatol; 2021 Dec; 48(12):1854-1862. PubMed ID: 34510527
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Guselkumab Efficacy after Withdrawal Is Associated with Suppression of Serum IL-23-Regulated IL-17 and IL-22 in Psoriasis: VOYAGE 2 Study.
    Gordon KB; Armstrong AW; Foley P; Song M; Shen YK; Li S; Muñoz-Elías EJ; Branigan P; Liu X; Reich K
    J Invest Dermatol; 2019 Dec; 139(12):2437-2446.e1. PubMed ID: 31207232
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year.
    Galluzzo M; Talamonti M; Bernardini N; Chiricozzi A; De Simone C; Bonifati C; Bruni P; Diotallevi F; Esposito M; Graceffa D; Hansel K; Loconsole F; Moretta G; Mugheddu C; Papini M; Richetta A; Skroza N; Atzori L; Fargnoli MC; Persechino S; Offidani A; Stingeni L; Peris K; Potenza C; Bianchi L
    Expert Opin Biol Ther; 2022 Dec; 22(12):1585-1592. PubMed ID: 35708257
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety in moderate-to-severe plaque psoriasis patients with latent tuberculosis treated with guselkumab and anti-tuberculosis treatments concomitantly: results from pooled phase 3 VOYAGE 1 & VOYAGE 2 trials.
    Puig L; Tsai TF; Bhutani T; Uy J; Ramachandran P; Song M; You Y; Gooderham M; Lebwohl M
    J Eur Acad Dermatol Venereol; 2020 Aug; 34(8):1744-1749. PubMed ID: 32289190
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Guselkumab is superior to fumaric acid esters in patients with moderate-to-severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active-comparator-controlled phase IIIb trial (POLARIS).
    Thaçi D; Pinter A; Sebastian M; Termeer C; Sticherling M; Gerdes S; Wegner S; Krampe S; Bartz H; Rausch C; Mensch A; Eyerich K
    Br J Dermatol; 2020 Aug; 183(2):265-275. PubMed ID: 31705526
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and safety of guselkumab in psoriasis patients who failed ustekinumab and/or anti-interleukin-17 treatment: A real-life 52-week retrospective study.
    Ruggiero A; Fabbrocini G; Cinelli E; Megna M
    Dermatol Ther; 2021 Jan; 34(1):e14673. PubMed ID: 33314658
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis.
    Blauvelt A; Tsai TF; Langley RG; Miller M; Shen YK; You Y; Yang YW; Papp KA; Puig L
    J Am Acad Dermatol; 2022 Apr; 86(4):827-834. PubMed ID: 34798201
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Successful long-term guselkumab treatment of severe plaque psoriasis in patients with class III obesity: A case series.
    Galluzzo M; Marcelli L; Fico A; Bianchi L; Talamonti M
    Skin Health Dis; 2024 Feb; 4(1):e289. PubMed ID: 38312241
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cost per response for guselkumab versus adalimumab in the United States using data from a head-to-head trial in moderate-to-severe plaque psoriasis.
    Teeple A; Muser E
    J Med Econ; 2019 Dec; 22(12):1268-1273. PubMed ID: 31199173
    [No Abstract]   [Full Text] [Related]  

  • 56. Etanercept and efalizumab for the treatment of psoriasis: a systematic review.
    Woolacott N; Hawkins N; Mason A; Kainth A; Khadjesari Z; Vergel YB; Misso K; Light K; Chalmers R; Sculpher M; Riemsma R
    Health Technol Assess; 2006 Nov; 10(46):1-233, i-iv. PubMed ID: 17083854
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Super responders to guselkumab treatment in moderate-to-severe psoriasis: a real clinical practice pilot series.
    Ruiz-Villaverde R; Rodriguez-Fernandez-Freire L; Armario-Hita JC; Pérez-Gil A; Galán-Gutiérrez M
    Int J Dermatol; 2022 Aug; 61(8):1029-1033. PubMed ID: 34731493
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1.
    Griffiths CEM; Papp KA; Song M; Miller M; You Y; Shen YK; Han C; Blauvelt A
    J Dermatolog Treat; 2022 Mar; 33(2):848-856. PubMed ID: 32660282
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluation of short-term (16-week) effectiveness and safety of guselkumab in patients with psoriasis: A prospective real-life study on the Chinese population.
    Zhuang JY; Li JS; Zhong YQ; Zhang FF; Li XZ; Su H; Zhang ZQ; Wang XH; Chen YF
    Dermatol Ther; 2021 Sep; 34(5):e15054. PubMed ID: 34228392
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Long-term efficacy and safety of apremilast in the treatment of plaques psoriasis: A real-world, single-center experience.
    Radi G; Campanati A; Diotallevi F; Rizzetto G; Martina E; Bobyr I; Giannoni M; Offidani A
    Dermatol Ther; 2021 Nov; 34(6):e15179. PubMed ID: 34704350
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.